A Study to Evaluate Avastin in Combination With Standard Chemotherapy to Treat Colorectal Cancer

Sponsor
Genentech, Inc.
Study ID
NCT00109070
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a multicenter, Phase III, randomized, active-controlled trial to evaluate the efficacy and safety of rhuMAb VEGF (Avastin) added to the standard first-line chemotherapy used to treat metastatic colorectal cancer. This trial will enroll approximately 900 subjects with histologically confirmed, previously untreated, bi-dimensionally measurable metastatic colorectal cancer.

Key Dates

First listed
Apr 25, 2005
Start date
Sep 30, 2000
Status verified
Jun 2013
Completion
Apr 30, 2003

Study Design

Allocation
RANDOMIZED
Primary purpose
TREATMENT

Related Studies